Αρχική World News FDA Approves New Interchangeable Biosimilar to Pertuzumab World News FDA Approves New Interchangeable Biosimilar to Pertuzumab Από Ogkologos - 3 Δεκεμβρίου, 2025 481 0 Facebook Twitter Google+ Pinterest WhatsApp Approval is based on comparisons across a broad range of structural and functional product quality attributes Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR EMA Recommends Extension of Indications for Selpercatinib 15 Απριλίου, 2026 EMA Recommends Extension of Therapeutic Indications for Enzalutamide 28 Μαρτίου, 2024 High Risk of BCSM at 20 Years in Men with Hormone... 1 Μαρτίου, 2024 Pembrolizumab Provides First-Ever Overall Survival Improvement in Kidney Cancer 21 Μαΐου, 2024 Φόρτωση περισσοτέρων HOT NEWS How Sharing My Story Helps Me Cope With an Advanced Brain... Jiffy Lube Surprises Volunteer Who Drives Cancer Patients To Treatment With... Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade... “No Person With Cancer or Survivor Should Ever Feel Alone”: A...